Professor Robert Clarke
Research groups
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- China Kadoorie Biobank
- HPS: Heart Protection Study
- PROCARDIS Sibling-pair Studies of Genetic Determinants of MI
- Re-survey and Follow-up of 1970 Whitehall Study
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
Websites
-
University of Cambridge
External Examiner in Epidemiology
-
London School of Hygiene and Tropical Medicine
External Examiner in Epidemiology
-
University College Dublin
External Examiner in Epidemiology
-
Faculty of Public Health Medicine, Royal College of Physicians of Ireland
External Examiner in Epidemiology
-
Swedish Cardiopulmonary Bioimage Study (SCAPIS)
Scientific Advisory Board
-
Irish Longitudinal Study on Aging (TILDA)
Scientific Advisory Board
-
Development of cardiovascular risk prediction model for Chinese adults
Research Group
Robert Clarke
MD, FRCP, FFPH, FFPHI, MSc, DCH
Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is a Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of Oxford and Consultant in Public Health Medicine and Director of the MSc course in Global Health Science. He qualified in clinical medicine in Ireland and worked for 5 years in internal medicine and 4 years in cardiology. After 2 years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in Cardiovascular Epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for occlusive vascular diseases. He led several large observational studies and meta-analyses of observational studies and randomized trials (eg, Whitehall study, PROCARDIS, CARDIoGRAMplusC4D, B-Vitamin Treatment Trialists’ Collaboration and the BEST-D trial). He also worked extensively on the Prospective Studies Collaboration and the China Kadoorie Biobank (CKB) study. He currently leads a research programme to assess the importance of blood pressure, blood lipids, and novel biomarkers (including genetic markers, cytokines, proteomics and metabolomics) for occlusive vascular diseases in the CKB study. His work has been widely cited (200 publications, H-index of 54) and is listed in Tomson Reuters’ Most Influential Scientific Minds 2014.
Recent publications
-
Heterogeneity in diagnosis and prognosis of ischaemic stroke subtypes: 9-year follow-up of 22000 cases in Chinese adults.
Journal article
Chun M. et al, (2023), Int J Stroke
-
Body Composition and Risk of Vascular-Metabolic Mortality Risk in 113 000 Mexican Men and Women Without Prior Chronic Disease.
Journal article
Gnatiuc Friedrichs L. et al, (2023), J Am Heart Assoc
-
Proteomic profiling identifies novel independent relationships between inflammatory proteins and myocardial infarction.
Journal article
Valdes-Marquez E. et al, (2023), Eur J Prev Cardiol
-
Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease.
Journal article
Clarke R. et al, (2023), Circ Res
-
Independent Relevance of Different Measures of Adiposity for Carotid Intima-Media Thickness in 40 000 Adults in UK Biobank.
Journal article
Pillay P. et al, (2023), J Am Heart Assoc, 12